Cargando…
Glycogen Synthase Kinase 3β: A New Gold Rush in Anti-Alzheimer’s Disease Multitarget Drug Discovery?: Miniperspective
[Image: see text] Alzheimer’s disease (AD), like other multifactorial diseases, is the result of a systemic breakdown of different physiological networks. As result, several lines of evidence suggest that it could be more efficiently tackled by molecules directed toward different dysregulated bioche...
Autores principales: | De Simone, Angela, Tumiatti, Vincenzo, Andrisano, Vincenza, Milelli, Andrea |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2020
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8016207/ https://www.ncbi.nlm.nih.gov/pubmed/33346659 http://dx.doi.org/10.1021/acs.jmedchem.0c00931 |
Ejemplares similares
-
PROTAC-Induced
Glycogen Synthase Kinase 3β Degradation
as a Potential Therapeutic Strategy for Alzheimer’s Disease
por: Guardigni, Melissa, et al.
Publicado: (2023) -
Amaryllidaceae Alkaloids as Potential Glycogen Synthase Kinase-3β Inhibitors
por: Hulcová, Daniela, et al.
Publicado: (2018) -
Cyclin Dependent
Kinase 9 Inhibitors for Cancer Therapy: Miniperspective
por: Sonawane, Yogesh A., et al.
Publicado: (2016) -
Successes and Challenges in
Phenotype-Based Lead Discovery
for Prion Diseases: Miniperspective
por: Ghaemmaghami, Sina, et al.
Publicado: (2014) -
Glycogen Synthase Kinase-3
por: Crouch, Peter, et al.
Publicado: (2011)